Author

Victoria Christenssen

Observed names: Christenssen, V, Christenssen, Victoria, V Christenssen, V. Christenssen

Observed institutions: University of Leeds, University Hospitals Birmingham NHS Foundation Trust, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Public Health England, National Institute for Health and Care Research, University of Oxford, Public Health Scotland, National Records of Scotland, Nepal Health Research Council, Oxford University Clinical Research Unit, Intensive Care National Audit & Research Centre, Oxford University Clinical Research Unit Indonesia, Newcastle University

OpenAlex ID: A5007864095

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

2019 · Guy De Backer, Piotr Jankowski, et al. · Atherosclerosis · 383

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease—A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V

2020 · Giulia Ferrannini, Dirk De Bacquer, et al. · Diabetes Care · 75

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology

2023 · Ramesh Nadarajah, Peter Ludman, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 21

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

2022 · Ramesh Nadarajah, Peter Ludman, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 20

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

Works count: 16

Citation count: 2,200

H-index: 12

I10-index: 12